RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 601–700 of 1,003
Wang, K., Baldwin, G. S., Nikfarjam, M., & He, H. Z. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3709 · Cited by 37
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
Mokhlis, H. A., Bayraktar, R., Kabil, N. N., Caner, A., Kahraman, N., Rodriguez‐Aguayo, C., Zambalde, É. P., Sheng, J., Karagoz, K., Kanlikilicer, P., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.019 · Cited by 38
Targeting ERK beyond the boundaries of the kinase active site in melanoma
Sammons, R. M., Ghose, R., Tsai, K. Y., & Dalby, K. N. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23047 · Cited by 38
Röck, R., Mayrhofer, J. E., Torres‐Quesada, O., Enzler, F., Raffeiner, A., Raffeiner, P., Feichtner, A., Huber, R. G., Koide, S., Taylor, S. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav8463 · Cited by 40
Development and Characterization of Six New Human Papillary Thyroid Carcinoma Cell Lines
Henderson, Y. C., Ahn, S., Ryu, J., Chen, Y., Williams, M. D., El‐Naggar, A. K., Gagea, M., Schweppe, R. E., Haugen, B. R., Lai, S. Y., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2624 · Cited by 37
Fang, B. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 41
“1) (see details in other review articles [18,19]).”
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
Kießling, M. K., Fontecedro, A. C., Samaras, P., Lang, S., Scharl, M. M., Aguzzi, A., Oldrige, D. A., Maris, J. M., & Rogler, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147682 · Cited by 37
“These mutations block GTPase activity and lock the RAS isoforms in continuous activation in which they signal to downstream effectors such as MEK and ERK [11].”
BackgroundOncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Zhang, D., Zhang, G., Hu, Z., Wu, L. W., Feng, Y., He, S., Zhang, Y., Hu, Z., Yang, L., Tian, T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1768 · Cited by 39
“DISCUSSION RAS signaling is one of the most studied biological pathways and plays important roles in tumorigenesis and cancer progression (17-21).”
BackgroundInfluentialLu, J., Harrison, R. A., Li, L., Zeng, M., Gondi, S., Scott, D., Gray, N. S., Engen, J. R., & Westover, K. D. (2017) · Structure · doi:10.1016/j.str.2017.07.003 · Cited by 38
“…RAS, the activated form for RAS, which transduces signals resulting in processes necessary for cancer such as cell growth and proliferation (Pylayeva-Gupta et al., 2011), invasiveness (Campbell and Der, 2004; Lundy et al., 1986), and evasion of immune surveillance (Seliger et al., 1998;…”
BackgroundSun, J., Sun, L., Li, J., Xu, J., Wan, Z., Ouyang, Z., Liang, L., Li, S., & Zeng, D. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.010 · Cited by 37
Critical role of oncogenic KRAS in pancreatic cancer (Review)
Liu, J., Ji, S., Liang, C., Qin, Y., Jin, K., Liang, D., Xu, W., Shi, S., Zhang, B., Liu, L., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5196 · Cited by 37
“Immune cells infiltrate around the lowest grade preinvasive lesions, but immunosuppressive cells, including macrophages, regulatory T cells and myeloid-derived suppressor cells (MDSC), predominate in the early response and persist through invasive cancer (14).”
InfluentialThe Allosteric Switch and Conformational States in Ras GTPase Affected by Small Molecules
Johnson, C. W., & Mattos, C. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00003-8 · Cited by 38
“Ras now is known to be involved not only in pathways controlling cell proliferation, but also apoptosis, invasion, survival, and angiogenesis [7].”
BackgroundInfluentialPark, K., Yang, H., Choi, J., Seo, S., Kim, D., Lee, C. H., Jeon, H., Kim, S., & Lee, D. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.028 · Cited by 36
“It is in fact well-known that negative and positive cross-talk occurs between the RAS/RAF/MEK/ERK/RSK and PI3K/AKT/mTOR pathways, whi c are downstream of RTK, and such signaling dynamics and resulting feed back loops might constitute a substantial hurdle to efforts to control the effect s of KRAS mutations [1, 5].”
BackgroundTherapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 37
Regulation of Renal Differentiation by Trophic Factors
Kurtzeborn, K., Cebrián, C., & Kuure, S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01588 · Cited by 46
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers
Lim, S. A., Zhou, J., Martinko, A. J., Wang, Y.-H., Filippova, E. V., Steri, V., Wang, D., Remesh, S. G., Liu, J., Hann, B. C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154604 · Cited by 38
Ballou, E. R., Kozubowski, L., Nichols, C. B., & Alspaugh, J. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003687 · Cited by 36
Zheng, W., Tayyari, F., Gowda, G. A. N., Raftery, D., McLamore, E. S., Shi, J. P., Porterfield, D. M., Donkin, S. S., Bequette, B. J., & Teegarden, D. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.03.012 · Cited by 37
Jeganathan, N., Predescu, D. N., Zhang, J., Sha, F., Bardita, C., Patel, M., Wood, S. J., Borgia, J. A., BALK, R. A., & Predescu, S. A. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0543-1 · Cited by 36
“known to drive cell proliferation and tumorigenesis [61].”
BackgroundLasota, J. P., Kowalik, A., Felisiak-Gołąbek, A., Zięba, S., Waloszczyk, P., Masiuk, M., Wejman, J., Szumiło, J., & Miettinen, M. (2019) · Modern Pathology · doi:10.1038/s41379-018-0163-y · Cited by 36
“NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) is a member of human RAS proto-oncogene family that encodes cell membrane-associated proteins involved in transduction of extracellular growth and differentiation signals [42].”
BackgroundHennessey, R. C., Holderbaum, A. M., Bonilla, A., Delaney, C. P., Gillahan, J. E., Tober, K. L., Oberyszyn, T. M., Zippin, J. H., & Burd, C. E. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12601 · Cited by 35
“TpN 61R mice, as transgenic overexpression can lead to protein mis-localization and aberrant downstream signal transduction (Omerovic and Prior, 2009; Pylayeva-Gupta et al., 2011).”
Kota, S., Hou, S., Guerrant, W., Madoux, F., Troutman, S. A., Fernández-Vega, V., Alekseeva, N., Madala, N., Scampavia, L. D., Kissil, J. L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0257-5 · Cited by 36
“Indeed, the RAS genes are the most frequently mutated oncogenes, with oncogenic mutations found in approximately 30% of all cancers [1, 2].”
Wu, C.-S., Wu, S., Chen, H.-C., Chu, C., Tang, H. F., Liu, H., Hong, Y., Huang, C. F., Huang, G.-C., & Su, C. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108227 · Cited by 37
An ultra-stable cytoplasmic antibody engineered for in vivo applications
Kabayama, H., Takeuchi, M., Tokushige, N., Muramatsu, S., Kabayama, M., Fukuda, M., Yamada, Y., & Mikoshiba, K. (2020) · Nature Communications · doi:10.1038/s41467-019-13654-9 · Cited by 35
Xue, L., Chen, F., Yue, F., Camacho, L., Kothapalli, S., Wei, G., Huang, S., Mo, Q., Ma, F., Li, Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05927-5 · Cited by 35
Targeting KRAS in Colorectal Cancer
Wang, C., & Fakih, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01022-0 · Cited by 37
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature
Thompson, S. K., Buckl, A. K., Dossetter, A. G., Griffen, E., & Gill, A. L. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1952984 · Cited by 35
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 37
“Single point mutations in RAS that promote constitutive RAS activation and tumorigenesis (Bos, 1989; Downward, 2003; Malumbres and Barbacid, 2003; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011; Ratner and Miller, 2015) and developmental disorders (Tidyman and Rauen, 2009; Rauen, 2013; Borrie et al.”
BackgroundTumor Microenvironment in Pancreatic Intraepithelial Neoplasia
Opitz, F. V., Häberle, L., Daum, A., & Esposito, I. (2021) · Cancers · doi:10.3390/cancers13246188 · Cited by 37
Ha, D. P., Huang, B., Wang, H., Rangel, D. F., Krieken, R. V., Liu, Z., Samanta, S., Neamati, N., & Lee, A. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100837 · Cited by 35
“[24] Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D.”
BackgroundViable pigs with a conditionally-activated oncogenic KRAS mutation
Li, S., Edlinger, M., Saalfrank, A., Flisikowski, K., Tschukes, A., Kurome, M., Zakhartchenko, V., Keßler, B., Saur, D., Kind, A., et al. (2015) · Transgenic Research · doi:10.1007/s11248-015-9866-8 · Cited by 39
“For example, different human KRAS-driven cancers can vary widely in their response to targeted therapies (Pylayeva-Gupta et al. 2011; Engelman et al. 2008).”
BackgroundPARVA Promotes Metastasis by Modulating ILK Signalling Pathway in Lung Adenocarcinoma
Huang, A.-H., Pan, S., Chang, W., Hong, Q., Chen, J. J. W., & Yu, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118530 · Cited by 36
“Metastasis and tumorigenesis are two major determinants that contribute to cancer progression and cancer-related death [2,3].”
BackgroundPalmitoylation and the trafficking of peripheral membrane proteins
Chamberlain, L. H., Lemonidis, K., Sanchez-Perez, M. C., Werno, M. W., Gorleku, O. A., & Greaves, J. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120243 · Cited by 35
Barceló, C., Paco, N., Beckett, A. J., Alvarez-Moya, B., Garrido, E., Gelabert, M., Tebar, F., Jaumot, M., Prior, I. A., & Agell, N. (2013) · Journal of Cell Science · doi:10.1242/jcs.123737 · Cited by 35
Isoform-specific Ras signaling is growth factor dependent
Hood, F. E., Klinger, B., Newlaczyl, A. U., Sieber, A., Dorel, M., Oliver, S. P., Coulson, J. M., Blüthgen, N., & Prior, I. A. (2019) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-10-0676 · Cited by 34
Sriskanthadevan-Pirahas, S., Deshpande, R., Lee, B., & Grewal, S. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007202 · Cited by 38
“Most notably, activating mutations in Ras and RAF occur in a large percentage of cancers, and lead to hyper-activation of ERK, which drives tumour formation in both epithelial and stem cells (Pylayeva-Gupta et al, 2011).”
BackgroundDeng, H. (2013) · Fly · doi:10.4161/fly.27007 · Cited by 36
Altered glucose metabolism in Harvey-rastransformed MCF10A cells
Zheng, W., Tayyari, F., Gowda, G. A. N., Raftery, D., McLamore, E. S., Porterfield, D. M., Donkin, S. S., Bequette, B. J., & Teegarden, D. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22079 · Cited by 39
“The ras proto-oncogene is frequently mutated in cancers [9,10] and affects a variety of processes involved in cancer progression.”
BackgroundBaldelli, E., Bellezza, G., Haura, E. B., Crinó, L., Cress, W. D., Deng, J., Ludovini, V., Sidoni, A., Schabath, M. B., Puma, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5941 · Cited by 35
“com/oncotarget greater frequencies in pancreas, colorectal and non-small cell lung cancer (NSCLC) [1].”
BackgroundOliveira-Santos, W., Ramos, D. D. A. R., Lucena-Araujo, A. R., de Oliveira, F. M., Rego, E. M., Pittella-Silva, F., & Saldanha‐Araújo, F. (2016) · Tumor Biology · doi:10.1007/s13277-016-4846-z · Cited by 34
The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria
Rohlenová, K., Neužil, J., & Rohlena, J. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0130 · Cited by 34
State of the art biological therapies in pancreatic cancer
Marco, M. D., Grassi, E., Durante, S., Vecchiarelli, S., Palloni, A., Macchini, M., Casadei, R., Ricci, C., Panzacchi, R., Santini, D., et al. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.55 · Cited by 37
Oncogenes: The Passport for Viral Oncolysis through PKR Inhibition
Fernandes, J. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s33378 · Cited by 34
Sirt1 protects from K‐Ras‐driven lung carcinogenesis
Costa‐Machado, L. F., Martín‐Hernández, R., Sánchez‐Luengo, M. Á., Hess, K., Vales‐Villamarín, C., Barradas, M., Lynch, C. J., de la Nava, D., Díaz‐Ruiz, A., de Cabo, R., et al. (2018) · EMBO Reports · doi:10.15252/embr.201643879 · Cited by 36
“One of the main transducers of mitogenic signals is the small GTPase family of Ras proteins, composed by three members in mammals: K-Ras, N-Ras, and H-Ras [38].”
InfluentialMEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
Xu, H., Zhou, S., Xia, H., Yu, H., Tang, Q., & Bi, F. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0309-6 · Cited by 34
Kobliakov, V. A. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919100018 · Cited by 34
Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
Qian, L. M., Chen, K., Wang, C., Chen, Z., Meng, Z., & Wang, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2604 · Cited by 36
“KRAS, HRAS, and NRAS (1, 3, 8, 9) were the first identified oncogenes, and it is now well established that about 25% of all human cancers harbor activating mutations in at least one of these proteins (8, 36).”
BackgroundRas, PI3K and mTORC2 – three's a crowd?
Smith, S. F., Collins, S. E., & Charest, P. G. (2020) · Journal of Cell Science · doi:10.1242/jcs.234930 · Cited by 37
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-07967-6 · Cited by 34
Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.016 · Cited by 36
Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L. (2018) · Oncogene · doi:10.1038/s41388-018-0289-x · Cited by 33
“KRAS encodes a small GTPase that mediates signals from growth factor receptors to downstream PI3K/AKT and MEK/ERK effector pathways [8].”
Padala, R. R., Karnawat, R., Viswanathan, S. B., Thakkar, A. V., & Das, A. B. (2017) · Molecular BioSystems · doi:10.1039/c6mb00786d · Cited by 33
Kanholm, T., Rentia, U., Hadley, M. M., Karlow, J. A., Cox, O. L., Diab, N., Bendall, M. L., Dawson, T., McDonald, J. I., Xie, W., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3485 · Cited by 35
Yang, M., Xiang, H., & Luo, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01619 · Cited by 33
Teh, J. T., Zhu, W., Ilkayeva, O., Li, Y., Gooding, J. R., Casey, P. J., Summers, S. A., Newgard, C. B., & Wang, M. (2014) · Oncogene · doi:10.1038/onc.2014.260 · Cited by 33
Update on Medullary Thyroid Cancer
Hu, M. I.-N., Ying, A. K., & Jiménez, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.02.004 · Cited by 36
KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
Naidoo, J., & Drilon, A. E. D. C. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_8 · Cited by 34
AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer
Welcker, D., Jain, M., Khurshid, S., Jokić, M., Höhne, M., Schmitt, A., Frommolt, P., Niessen, C. M., Spiro, J., Persigehl, T., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0054-6 · Cited by 35
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 34
Chen, K., Shang, Z., Dai, A.-L., & Dai, P.-L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117816 · Cited by 34
Sarkar, D., Olejniczak, E. T., Phan, J., Coker, J. A., Sai, J., Arnold, A. L., Beesetty, Y., Waterson, A. G., & Fesik, S. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00511 · Cited by 33
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
Nollmann, F. I., & Ruess, D. A. (2020) · Biomedicines · doi:10.3390/biomedicines8080281 · Cited by 35
Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells
Maniam, S., & Maniam, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189722 · Cited by 37
The mechanism of activation of MEK1 by B-Raf and KSR1
Maloney, R., Zhang, M., Liu, Y., Jang, H., & Nussinov, R. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04296-0 · Cited by 34
Viscoelastic stiffening of gelatin hydrogels for dynamic culture of pancreatic cancer spheroids
Nguyen, H. D., & Lin, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.02.010 · Cited by 37
AKT regulates NPM dependent ARF localization and p53mut stability in tumors
Hamilton, G., Abraham, A., Morton, J. P., Sampson, O. L., Pefani, D., Khoronenkova, S. V., Grawenda, A. M., Papaspyropoulos, A., Jamieson, N. B., McKay, C. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2178 · Cited by 39
“Activating mutations occur at residues G12-, G13- or Q61KRAS and result in a range of amino acid substitutions that can differ in the effector pathway and/or potency of activation [76].”
BackgroundComparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
Kleiman, L. B., Krebs, A. M., Kim, S. Y., Hong, T. S., & Haigis, K. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082982 · Cited by 33
“Mutations in K-RAS are most frequently found at codons 12 and 13 and compromise GTP hydrolysis stimulated by GTPase-activating proteins (GAPs), resulting in hyperactive K-RAS and uncontrolled proliferation [19].”
InfluentialAn Overview of Molecular Cancer Pathogenesis, Prognosis, and Diagnosis
Cullen, J. M., & Breen, M. (2016) · Wiley eBooks · doi:10.1002/9781119181200.ch1 · Cited by 50
KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice
Tang, F., Hsieh, T., Hsu, C., Lin, H., Long, C., Cheng, K., & Tsai, E. (2016) · International Journal of Cancer · doi:10.1002/ijc.30591 · Cited by 33
“From our results in several studies in animal models, we found that K-ras mutation in epithelial cells led to hyperproliferative, hyperplastic glands and enhanced tumor formation on the ovary surface.(9,18,33,34) For primary carcinosarcoma, although we found that K-ras mutation rate is much less frequent in ovarian ca…”
ResultMET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis
Cataisson, C., Michalowski, A. M., Shibuya, K., Ryscavage, A. O., Klosterman, M., Wright, L. N., Dubois, W., Liu, F., Zhuang, A., Rodrigues, K. B., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf5106 · Cited by 34
Tian, H., Pang, J., Qin, K., Yuan, W.-M., Kong, J., Ma, H., He, J., Yang, X., Luo, Y., Lu, Y., et al. (2019) · Biotechnology Journal · doi:10.1002/biot.201900107 · Cited by 34
Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
Tsang, Y. H., Wang, Y., Kong, K., Grzeskowiak, C. L., Zagorodna, O., Dogruluk, T., Lu, H., Villafañe, N., Bhavana, V. H., Moreno, D., et al. (2020) · eLife · doi:10.7554/elife.48963 · Cited by 36
“At late stages of tumor development, autophagy increases the ability of tumor cells to cope with endogenous stress and increases chemotherapy or radiotherapy resistance (Pylayeva-Gupta et al., 2011; White, 2012) thus promoting tumorigenic behavior.”
BackgroundRyu, W., Han, G., Lee, S.-H., & Choi, K. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.076 · Cited by 32
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
Xiao, L., Hu, Q., Peng, Y., Zheng, K., Zhang, T., Yang, L., Wang, Z., Tang, W., Yu, J., Xiao, Q., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-09049-z · Cited by 33
“The Ras/ERK signaling pathway participates in the metabolic reprogramming that allows tumor cells to thrive under the conditions of limited oxygen supply that they encounter during tumor growth and progression [35].”
BackgroundEvelyn, C. R., Biesiada, J., Duan, X., Tang, H., Shang, X., Papoian, R., Seibel, W. L., Nelson, S., Meller, J., & Zheng, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634493 · Cited by 30
Sanders, J. M., Wampole, M. E., Chen, C.-P., Sethi, D., Singh, A., Dupradeau, F., Wang, F., Gray, B. D., Thakur, M. L., & Wickstrom, E. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp4064966 · Cited by 32
RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins
Çetin, M. S., Evenson, W. E., Gross, G. G., Jalali‐Yazdi, F., Krieger, D., Arnold, D. B., Takahashi, T. T., & Roberts, R. W. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.008 · Cited by 32
“K- and H-Ras have been identified as mediators of malignant characteristics [1,2], and oncogenic mutations in these proteins are commonly observed [3,4].”
BackgroundTsao, W.-C., & Eckert, K. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103255 · Cited by 32
Tedeschi, A., Schischlik, F., Rocchetti, F., Popow, J., Ebner, F., Gerlach, D., Geyer, A., Santoro, V., Boghossian, A. S., Rees, M. G., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0386 · Cited by 36
“KRAS mutations result in the accumulation of active (GTP-bound, “ON”) KRAS and persistent pathogenic activation of downstream signaling (7).”
Park, H., Kim, Y., Sul, J., Jeong, I. G., Yi, H., Ahn, J. B., Kang, J. S., Yun, J., Hwang, J. J., & Kim, C. (2015) · The Prostate · doi:10.1002/pros.23057 · Cited by 34
“The RAF, MEK, and ERK kinase cascade is also upregulated [10], although mutation of RAS is rare in prostate cancer (6% HRAS, 8% KRAS, and 2% NRAS) [11,12].”
BackgroundMitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation
Bettoun, A., Joffre, C., Zago, G., Surdez, D., Vallerand, D., Gündoğdu, R., Sharif, A. A. D., Gómez-Ferrer, M., Cascone, I., Meunier, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9875 · Cited by 32
“The small GTPase family of Ras proteins are frequently mutated proto-oncogenes in human cancers with a high prevalence in colorectal, pancreatic and lung cancers, where cancers carrying activating mutations in Ras are linked to particularly poor prognosis [10].”
BackgroundTime-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK
Kubiniok, P., Lavoie, H., Therrien, M., & Thibault, P. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.065128 · Cited by 34
Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 31
Wang, H., Zhang, L., Miao, Z., Zhang, M., Liu, H., He, Q., Meng, J., Wen, L., Ke, Z., Zha, Z., et al. (2021) · Materials Horizons · doi:10.1039/d0mh01992e · Cited by 32
Jeong, A., Cheng, S., Zhong, R., Bennett, D. A., Bergö, M. O., & Li, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01231-5 · Cited by 32
Li, C., Liu, F., Xu, Y., Guo, B., Li, G., Yin, J., He, G., Yang, C., Xu, L., Li, S., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00884-y · Cited by 31
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 33
Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity
Murthy, P. K. L., Xi, R., Mendoza, D. A., Everitt, J. I., Koçak, D. D., Kobayashi, Y., Bözec, A., Vicent, S., Ding, S., Crawford, G. E., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.01.006 · Cited by 31
Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome
Tora, R., Welch, J. M., Sun, J. H., Agarwal, S. K., Bell, D. A., Merino, M. J., Weinstein, L. S., Simonds, W. F., & Jha, S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad368 · Cited by 34
Ahmad, R. M., Ali, B. R., Al-Jasmi, F. A., Sinnott, R., Dhaheri, N. A., & Mohamad, M. S. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad479 · Cited by 37
Broaders, K. E., Cerchiari, A. E., & Gartner, Z. J. (2015) · Integrative Biology · doi:10.1039/c5ib00240k · Cited by 31
Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
Okumura, S., & Jänne, P. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2365 · Cited by 30
Regulation of hyphal morphogenesis by Ras and Rho small GTPases
Arkowitz, R. A., & Bassilana, M. (2015) · Fungal Biology Reviews · doi:10.1016/j.fbr.2015.02.003 · Cited by 32
Corrado, M., Scorrano, L., & Campello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8727 · Cited by 35
“In particular, single-point mutations in RAS lead to its constitutively active signalling in many solid cancers such as pancreas, lung and colorectal cancer [30].”
BackgroundIGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
O’Flanagan, C. H., O’Shea, S., Lyons, A., Fogarty, F., McCabe, N., Kennedy, R. D., & O’Connor, R. (2016) · Oncotarget · doi:10.18632/oncotarget.10862 · Cited by 31
“The canonical IGF signalling pathway recruited by the IRS scaffolding proteins activates PI3-Kinase, Akt, and Ras, all of which are potent oncogenes that are deregulated in many cancers [4, 5].”
BackgroundGe, Z., Gu, Y., Han, Q., Zhao, G., Li, M., Li, J., Chen, B., Sun, T., Dovat, S., Gale, R. P., et al. (2016) · Scientific Reports · doi:10.1038/srep38004 · Cited by 31
ATF1 and RAS in exosomes are potential clinical diagnostic markers for cervical cancer
Shi, Y., Wang, W. T., Yang, B., & Tian, H. (2017) · Cell Biochemistry and Function · doi:10.1002/cbf.3307 · Cited by 31
“RAS proteins are small GTPases that mediate downstream of growth factor receptor signalling and therefore are essential for cell proliferation, survival, and differentiation.(26) RAS can activate several downstream effectors, including the PI3K‐AKT‐mTOR pathway, which is involved in cell survival, and the RAS‐RAF‐MEK‐…”
BackgroundLeiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., Bladt, F., Aebersold, D. M., & Zimmer, Y. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.001 · Cited by 30
K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135131 · Cited by 32
“Oncogenic K-Ras activates signaling pathways, including Raf/MEK/ERK, PI3K/Akt, and RalGDS.”
Background
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.